Cryoport (CYRX) Q3 2025 Earnings Transcript

Cryoport reported 36% year-over-year growth in commercial cell and gene therapy revenue to $8.3 million, while Life Sciences Services rose 16% and adjusted EBITDA loss narrowed to $600,000. Management raised full-year 2025 revenue guidance to $170 million-$174 million and highlighted positive operating cash flow of $2.2 million, though it cautioned that the government shutdown, tariffs, and startup costs could weigh on near-term margins. The quarter also featured new product launches, first IntegriCell clients, and the opening of a 55,000-square-foot Paris supply chain center.

Analysis

CYRX is finally transitioning from a story stock to a cash-generating operating platform, and that matters because the market tends to re-rate these businesses only when the “proof of utilization” phase starts. The near-term earnings quality is still noisy, but the combination of positive operating cash flow, sharply improved EBITDA, and a more diversified mix suggests the business is moving from pure pipeline optionality toward a more durable compounding model.

The bigger second-order effect is that CYRX is quietly becoming a toll collector on the institutionalization of cell therapy. If commercial therapies continue to move earlier in line and into community settings, the company’s service intensity per patient can rise faster than headline therapy counts, which supports revenue even if trial starts are choppy. That said, the market may be underestimating how lumpy 2026 can be: product revenue is still cyclical, and the new facilities will likely suppress margins before utilization catches up.

The cleanest contrarian point is that the best bull case is not “more trials,” but “higher workflow density per approved therapy.” That favors CYRX over pure-development names exposed to funding risk, and it also explains why a softening in gene therapy is not necessarily a thesis break—cell therapy and commercialization are doing the heavy lifting. The main risk is a timing mismatch: if regulatory shutdowns, capital spending delays, or customer portfolio pruning push orders into 2026 while startup costs hit now, the stock can look optically expensive long before the operating leverage arrives.

Key Decisions for Investors

• Long CYRX on a 3-6 month horizon as a cash-flow inflection trade; target a re-rating if the market starts capitalizing 2026 EBITDA leverage, but size modestly because margin expansion will likely lag revenue by 2-3 quarters.
• Buy CYRX Jan-2027 calls or call spreads to express upside from facility utilization and commercial therapy ramp with limited downside; best risk/reward if implied vol remains below the historical event-driven range.
• Pair long CYRX / short a basket of funding-sensitive preclinical biotech names (e.g., XBI constituents without commercial revenue) for a 6-12 month relative-value trade; thesis is that CYRX benefits from commercialization while early-stage names remain hostage to capital markets.
• Avoid chasing after sharp post-earnings moves; prefer adding on pullbacks tied to shutdown-related headline risk, since those delays are timing noise rather than demand destruction.
• Watch for a catalyst window around Q4/Q1 updates on Paris utilization and IntegriCell ramp; if management confirms accelerating throughput, use that as the signal to press the long.